© 2001 by Oxford University Press
Journal of the National Cancer Institute, Vol. 93, No. 6, 463-471,
March 21, 2001
© 2001 Oxford University Press
Activity of a Novel bcl-2/bcl-xL-Bispecific Antisense Oligonucleotide Against Tumors of Diverse Histologic Origins
Affiliations of authors: O. Gautschi, S. Tschopp, R. A. Olie, S. H. Leech, A. P. Simões-Wüst, A. Ziegler, R. A. Stahel, U. Zangemeister-Wittke (Division of Oncology, Department of Internal Medicine), B. Odermatt (Department of Pathology), University Hospital, Zurich, Switzerland; B. Baumann, Institute of Biochemistry, Swiss Federal Institute of Technology, Zurich; J. Hall, Novartis Pharma AG, Basel, Switzerland.
Correspondence to: Uwe Zangemeister-Wittke, Ph.D., Division of Oncology, Department of Internal Medicine, University Hospital, Zurich, Switzerland (e-mail: uwe.zangemeister{at}dim.usz.ch).
Background: Increased expression of the anti-apoptotic proteins Bcl-2 and Bcl-xL is involved in the development and progression of many tumors. We recently reported that the bcl-2/bcl-xL-bispecific antisense oligonucleotide 4625 induces apoptosis in lung carcinoma cells. To further assess the therapeutic potential of oligonucleotide 4625, we investigated its effect on a series of human tumor cell lines of diverse histologic origins in vitro and in vivo. Methods: Oligonucleotide 4625-mediated inhibition of bcl-2 and bcl-xL expression in vitro was measured in breast carcinoma cells with the use of reverse transcription–polymerase chain reaction (PCR), real-time PCR, and western blotting. Cytotoxicity was assessed in several different cell lines by measurement of tumor cell growth, propidium iodide uptake, and nuclear apoptosis. The in vivo activity of oligonucleotide 4625 was determined by the inhibition of growth of established tumor xenografts in nude mice, immunohistochemical staining of Bcl-2 and Bcl-x proteins in the tumors, and western blotting of tumor lysates. Apoptosis in tumor xenografts was detected with the use of in situ TUNEL (i.e., terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-digoxigenin nick end labeling) staining. All statistical tests are two-sided. Results: In breast carcinoma cells, oligonucleotide 4625 treatment reduced bcl-2 and bcl-xL messenger RNA levels in a dose-dependent manner. At 600 nM, oligonucleotide 4625 reduced Bcl-2 and Bcl-xL protein levels to 25% (95% confidence interval [CI] = 16% to 34%) and 20% (95% CI = 14% to 26%), respectively, of the levels in untreated cells and it decreased viability in all cell lines mainly by inducing apoptosis. In vivo, oligonucleotide 4625 statistically significantly inhibited the growth of breast and colorectal carcinoma xenografts by 51% (95% CI = 28% to 74%) and 59% (95% CI = 44% to 74%), respectively, relative to those treated with control oligonucleotide 4626; it also reduced Bcl-2 and Bcl-xL protein levels and induced tumor cell apoptosis. Conclusion: The bcl-2/bcl-xL-bispecific antisense oligonucleotide 4625 merits further study as a novel compound for cancer therapy.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. N. Danial BCL-2 Family Proteins: Critical Checkpoints of Apoptotic Cell Death Clin. Cancer Res., December 15, 2007; 13(24): 7254 - 7263. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Zhang, J. J. Peairs, P. Yang, J. Tyrrell, J. Roberts, R. Kole, and G. J. Jaffe The Importance of Bcl-xL in the Survival of Human RPE Cells Invest. Ophthalmol. Vis. Sci., August 1, 2007; 48(8): 3846 - 3853. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hussain, A. Pluckthun, T. M. Allen, and U. Zangemeister-Wittke Chemosensitization of carcinoma cells using epithelial cell adhesion molecule-targeted liposomal antisense against bcl-2/bcl-xL Mol. Cancer Ther., December 1, 2006; 5(12): 3170 - 3180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hachem and R. B. Gartenhaus Oncogenes as molecular targets in lymphoma Blood, September 15, 2005; 106(6): 1911 - 1923. [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Harris, M. J. Fischer, J. R. Hotchkiss, B. P. Monia, S. H. Randell, J. R. Harkema, and Y. Tesfaigzi Bcl-2 Sustains Increased Mucous and Epithelial Cell Numbers in Metaplastic Airway Epithelium Am. J. Respir. Crit. Care Med., April 1, 2005; 171(7): 764 - 772. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yamanaka, M. E. Gleave, I. Hara, M. Muramaki, and H. Miyake Synergistic antitumor effect of combined use of adenoviral-mediated p53 gene transfer and antisense oligodeoxynucleotide targeting clusterin gene in an androgen-independent human prostate cancer model Mol. Cancer Ther., February 1, 2005; 4(2): 187 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Milella, D. Trisciuoglio, T. Bruno, L. Ciuffreda, M. Mottolese, A. Cianciulli, F. Cognetti, U. Zangemeister-Wittke, D. Del Bufalo, and G. Zupi Trastuzumab Down-Regulates Bcl-2 Expression and Potentiates Apoptosis Induction by Bcl-2/Bcl-XL Bispecific Antisense Oligonucleotides in HER-2Gene-Amplified Breast Cancer Cells Clin. Cancer Res., November 15, 2004; 10(22): 7747 - 7756. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Real, Y. Cao, R. Wang, Z. Nikolovska-Coleska, J. Sanz-Ortiz, S. Wang, and J. L. Fernandez-Luna Breast Cancer Cells Can Evade Apoptosis-Mediated Selective Killing by a Novel Small Molecule Inhibitor of Bcl-2 Cancer Res., November 1, 2004; 64(21): 7947 - 7953. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Rashmi, S. Kumar, and D. Karunagaran Ectopic expression of Bcl-XL or Ku70 protects human colon cancer cells (SW480) against curcumin-induced apoptosis while their down-regulation potentiates it Carcinogenesis, October 1, 2004; 25(10): 1867 - 1877. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Sakurai, K. Itoh, H. Higashitsuji, T. Nagao, K. Nonoguchi, T. Chiba, and J. Fujita A Cleaved Form of MAGE-A4 Binds to Miz-1 and Induces Apoptosis in Human Cells J. Biol. Chem., April 9, 2004; 279(15): 15505 - 15514. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Hayward, J. S. Macpherson, J. Cummings, B. P. Monia, J. F. Smyth, and D. I. Jodrell Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect Mol. Cancer Ther., February 1, 2004; 3(2): 169 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Stassi, M. Todaro, M. Zerilli, L. Ricci-Vitiani, D. Di Liberto, M. Patti, A. Florena, F. Di Gaudio, G. Di Gesu, and R. De Maria Thyroid Cancer Resistance to Chemotherapeutic Drugs via Autocrine Production of Interleukin-4 and Interleukin-10 Cancer Res., October 15, 2003; 63(20): 6784 - 6790. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Simstein, M. Burow, A. Parker, C. Weldon, and B. Beckman Apoptosis, Chemoresistance, and Breast Cancer: Insights From the MCF-7 Cell Model System Experimental Biology and Medicine, October 1, 2003; 228(9): 995 - 1003. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Hayward, J. S. Macpherson, J. Cummings, B. P. Monia, J. F. Smyth, and D. I. Jodrell Antisense Bcl-xl Down-Regulation Switches the Response to Topoisomerase I Inhibition from Senescence to Apoptosis in Colorectal Cancer Cells, Enhancing Global Cytotoxicity Clin. Cancer Res., July 1, 2003; 9(7): 2856 - 2865. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Tortora, R. Caputo, V. Damiano, R. Caputo, T. Troiani, B. M. Veneziani, S. De Placido, A. R. Bianco, U. Zangemeister-Wittke, and F. Ciardiello Combined Targeted Inhibition of bcl-2, bcl-XL, Epidermal Growth Factor Receptor, and Protein Kinase A Type I Causes Potent Antitumor, Apoptotic, and Antiangiogenic Activity Clin. Cancer Res., February 1, 2003; 9(2): 866 - 871. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gradilone, P. Gazzaniga, D. Ribuffo, S. Scarpa, E. Cigna, F. Vasaturo, U. Bottoni, D. Innocenzi, S. Calvieri, N. Scuderi, et al. Survivin, bcl-2, bax, and bcl-X Gene Expression in Sentinel Lymph Nodes From Melanoma Patients J. Clin. Oncol., January 15, 2003; 21(2): 306 - 312. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Gautschi, U. Zangemeister-Wittke, and R. A. Stahel Comment on "A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer", by C. M. Rudin et al. (Ann Oncol 2002; 13: 539-545) Ann. Onc., January 1, 2003; 14(1): 170 - 170. [Full Text] [PDF]
|
|
|
|
|
|
D. R. Mercatante, J. L. Mohler, and R. Kole Cellular Response to an Antisense-mediated Shift of Bcl-x Pre-mRNA Splicing and Antineoplastic Agents J. Biol. Chem., December 13, 2002; 277(51): 49374 - 49382. [Abstract] [Full Text] [PDF]
|
|